About: Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China
Creator	Peng, Cheng Dong, Lan Chen, Dayi Pan, Xiaoqi Yang, Nian
Source	Elsevier; Medline; PMC
abstract	The fight against the novel coronavirus pneumonia (namely COVID-19) that seriously harms human health is a common task for all mankind. Currently, development of drugs against the novel coronavirus (namely SARS-CoV-2) is quite urgent. Chinese medical workers and scientific researchers have found some drugs to play potential therapeutic effects on COVID-19 at the cellular level or in preliminary clinical trials. However, more fundamental studies and large sample clinical trials need to be done to ensure the efficacy and safety of these drugs. The adoption of these drugs without further testing must be careful. The relevant articles, news, and government reports published on the official and Preprint websites, PubMed and China National Knowledge Infrastructure (CNKI) databases from December 2019 to April 2020 were searched and manually filtered. The general pharmacological characteristics, indications, adverse reactions, general usage, and especially current status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable medication and the development of specific drugs for the treatment of COVID-19.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1016/j.virusres.2020.198057
bibo:pmid	32531236
has license	no-cc
sha1sum (hex)	fc42f5385bd73a8731f4e70da3ea8148002aeb25
schema:url	https://doi.org/10.1016/j.virusres.2020.198057
resource representing a document's title	Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China
has PubMed Central identifier	PMC7282797
has PubMed identifier	32531236
schema:publication	Virus Res
resource representing a document's body	covid:fc42f5385bd73a8731f4e70da3ea8148002aeb25#body_text
is schema:about of	named entity 'active ingredients' named entity 'general' named entity 'COVID-19' named entity 'China' named entity 'stem cells' named entity 'products' named entity 'COVID-19' named entity 'pharmacological' named entity 'Biological products' named entity 'active ingredients' named entity 'COVID-19' named entity 'pneumonia' named entity 'coronavirus' named entity 'coronavirus' named entity 'China' named entity 'COVID' named entity 'COVID-19' named entity 'convalescent plasma' named entity 'structures' named entity 'vaccines' named entity 'interferon-α' named entity 'pneumonia' named entity 'Chinese herbal' named entity 'adverse reactions' named entity 'PRESCRIPTIONS' named entity 'CHEMICAL' named entity 'vaccines' named entity 'stem cells' named entity 'SARS-CoV-2' named entity 'ACTIONS' named entity 'COVID-19' named entity 'DRUGS' named entity 'N A' named entity 'INJECTION' named entity 'CONVALESCENT PLASMA' named entity 'TREATMENT' named entity 'COVID' named entity 'China' named entity 'Abstract' named entity 'Chinese' named entity 'prescriptions' named entity 'COVID-19' named entity 'COVID-19' named entity 'practical effects' named entity 'usage' named entity 'chemical' named entity 'adverse reactions' named entity 'SARS-CoV-2' named entity 'Various' named entity 'Highlights' named entity 'Journal' named entity 'Potential' named entity 'CHEMICAL STRUCTURES' named entity 'EFFECTIVE' named entity 'ADVERSE REACTIONS' named entity 'interferon-α' named entity 'chemical' named entity 'pharmacological' named entity 'COVID-19' named entity 'GENERAL' named entity 'injection' named entity 'preparations' named entity 'effective' named entity 'convalescent' named entity 'China' named entity 'pneumonia' named entity 'COVID-19' named entity 'treat' named entity 'REVIEWED' named entity 'ABSTRACT' named entity 'compound' named entity 'plasma' named entity 'BIOLOGICAL PRODUCTS' named entity 'PHARMACOLOGICAL' named entity 'COMPOUND' named entity 'COVID-19 TREATMENT' named entity 'EFFECTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software